Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HEC169096 · 1 trial · 1 indication
Determination of Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of HEC169096
As assessed by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
| Arm | Type | Description |
|---|---|---|
| HEC169096 | EXPERIMENTAL | Multiple doses of HEC169096 |
| Name | Type | Description |
|---|---|---|
| HEC169096 | DRUG | Multiple doses of HEC169096 during Phase 2；Oral dose of HEC169096 as determined during Phase 2. |
Inclusion Criteria: * Phase 1：Pathologically documented, definitively diagnosed non-resectable advanced solid tumor. * Phase 2： All participants must have an oncogenic RET-rearrangement/fusion or mutation (excluding synonymous, frameshift, and nonsense mutations) solid tumor. * Participants has Eas...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
HEC169096 is an investigational small molecule being studied for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated in patients with advanced solid tumors to assess its safety and potential efficacy.
The specific molecular target of HEC169096 has not been disclosed. It is a small molecule therapeutic being developed for oncology, specifically for advanced solid tumors. The mechanism of action is not publicly detailed, and the drug is currently in early-stage clinical trials to determine its effects.
HEC169096 is being developed by Sunshine Biopharma Inc., a biopharmaceutical company traded on the stock market under the ticker symbol SBFM. The company is conducting clinical research on this investigational drug for the treatment of advanced solid tumors.
HEC169096 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory agencies. The ongoing Phase 1 trial is recruiting participants to evaluate the drug's safety, tolerability, and pharmacokinetics in patients with advanced solid tumors.
HEC169096 is being studied in a Phase 1 clinical trial registered as NCT05451602, titled 'HEC169096 in Participants With Advanced Solid Tumors.' The trial is recruiting 456 participants in China, with an age minimum of 18 years, and is open to all sexes. It is an uncontrolled, non-randomized study.
No alternative names for HEC169096 have been reported. It is a distinct investigational compound developed by Sunshine Biopharma Inc. and is not known to be identical to any other marketed or investigational drug.